Aclidinium bromide clinical trials
A product of Aclidinium; its studies count on that page too.
How each study uses aclidinium bromide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 23 Jul 2012 · TUDORZA PRESSAIR · NDA 202450 (FDA, Drugs@FDA)
- European Union
- 20 Jul 2012 · Eklira Genuair · EMEA/H/C/002211 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
30 studies that test it; most in 2009 (6)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 6 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 27 · Other 3
AstraZeneca (26) · University of Dundee (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · University of Milan (1) · Daewoong Pharmaceutical Co. LTD. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Aclidinium
- One of Cholinergic Antagonists source
- One of Antimuscarinics source
Studies
Open first, then newest update. How each study uses aclidinium bromide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 30
- Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD PatientsCompletedPhase 3AstraZenecaNCT03022097Written as Aclidinium bromide/formoterol Fixed-Dose CombinationHow we know
- A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese ParticipantsCompletedPhase 1AstraZenecaNCT03276052Written as Aclidinium Bromide 400 μgHow we know
- Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC TrialCompletedPhase 4University of DundeeNCT02972476Written as Budesonide & formoterol fumarate and Aclidinium bromideHow we know
- The Effects of Inhaled Aclidinium Bromide/Formoterol Fumarate on Inspiratory Pleural Pressures in SmokersCompletedPhase 3McGill University Health Centre/Research Institute of the McGill University Health CentreNCT03104634Written as Aclidinium bromide/formoterol fumarate dihydrateHow we know
- Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.CompletedPhase 4AstraZenecaNCT01966107Written as Aclidinium BromideHow we know
- AMPLIFY - D6571C00001 Duaklir USA Phase III StudyCompletedPhase 3AstraZenecaNCT02796677Written as Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)How we know
- To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary DiseaseWithdrawnPhase 4AstraZenecaNCT03181880Written as Aclidinium bromide/formoterol fumarate combinationHow we know
- Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedPhase 3AstraZenecaNCT01437540Written as Aclidinium Bromide/Formoterol FumarateHow we know
- Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3AstraZenecaNCT01572792Written as Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)How we know
- BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGHCompletedPhase 4AstraZenecaNCT02375724Written as Aclidinium BromideHow we know
- Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)CompletedPhase 3AstraZenecaNCT01044459Written as Aclidinium Bromide 200 µgHow we know
- Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3AstraZenecaNCT01437397Written as Aclidinium Bromide/Formoterol FumarateHow we know
- Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose CombinationCompletedPhase 3AstraZenecaNCT01462942Written as Aclidinium Bromide/Formoterol FumarateHow we know
- Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)CompletedPhase 3AstraZenecaNCT01045161Written as Aclidinium bromideHow we know
- Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.CompletedPhase 2AstraZenecaNCT01120093Written as Aclidinium bromide 100 μg bidHow we know
- Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)CompletedPhase 3AstraZenecaNCT00891462Written as Aclidinium bromideHow we know
- Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)CompletedPhase 3AstraZenecaNCT00970268Written as Aclidinium bromideHow we know
- A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3AstraZenecaNCT00363896Written as Aclidinium bromideHow we know
- A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3AstraZenecaNCT00500318Written as Aclidinium BromideHow we know
- Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedPhase 2AstraZenecaNCT00868231Written as Aclidinium bromide 400 μg bidHow we know
See all 30 studies that test aclidinium bromide →
As the comparator · 1 — what is tested is compared with aclidinium bromide
Codes
What other systems call aclidinium bromide · ClinicalTrials.gg INT005477
- MeSH (NLM) C542859aclidinium bromideOne source NLM
- UNII (FDA) UQW7UF9N91ACLIDINIUM BROMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 1303097Confirmed FDA, Wikidata
- Wikidata Q27888207aclidinium bromideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C75999Aclidinium BromideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C542859 | aclidinium bromide | One source NLM |
| UNII (FDA) | UQW7UF9N91 | ACLIDINIUM BROMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1303097 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27888207 | aclidinium bromide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C75999 | Aclidinium Bromide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.